MCK
McKesson Corporation
MCK has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MCK overall, supported by stronger fundamentals and stronger modeled upside.
MCK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
MCK's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MCK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $654 | -39% |
| Forward | 22x | $1,077 | — |
| Fair | 26x | $1,019 | -5.4% |
| Current | 28x | $1,077 | — |
| Expensive | 31x | $1,206 | +12% |
Historical ranges are pointers, not guarantees.
MCK's PE is in its expensive range at 28x. If earnings grow as analysts expect, today's price would be 22x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over MCK in the historical PE scenario, which offers more potential upside but is not a forecast.
MCK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for MCK, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MCK on the outlook, with more favorable profitability expectations.
MCK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $48.95 | +26% |
| Q3 2026 | $38.80 | +21% |
| Q2 2026 | $37.28 | +49% |
| Q1 2026 | $38.38 | +49% |
| Q4 2025 | $34.66 | +59% |
| Q3 2025 | $32.02 | +66% |
| Q2 2025 | $24.97 | +12% |
| Q1 2025 | $25.72 | +15% |
| Q4 2024 | $21.85 | -0.9% |
MCK has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MCK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $111B | +7.6% |
| Q2 2026 | $105.4B | +7.7% |
| Q1 2026 | $96.3B | +6% |
| Q4 2025 | $106.2B | +11% |
| Q3 2025 | $103.2B | +10% |
| Q2 2025 | $97.8B | +23% |
| Q1 2025 | $90.8B | +19% |
| Q4 2024 | $95.3B | +18% |
MCK's revenue has grown year over year every quarter since late 2020: $111B last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.4% | +0.1 points |
| Q2 2026 | 1.3% | +0.2 points |
| Q1 2026 | 2.2% | +0.5 points |
| Q4 2025 | 1.5% | +0.3 points |
| Q3 2025 | 1.4% | +0.7 points |
| Q2 2025 | 1.1% | -0.2 points |
| Q1 2025 | 1.8% | +0.2 points |
| Q4 2024 | 1.3% | +0.5 points |
MCK's operating margin was 1.4% last quarter, about level with the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MCK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MCK on profitability, with a higher operating margin.
MCK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3B | +30% |
| Q2 2026 | -$332M | +$697M |
| Q1 2026 | $3.3B | -56% |
| Q4 2025 | $1.1B | +$3.6B |
| Q3 2025 | $2.3B | +18% |
| Q2 2025 | -$1B | +$457M |
| Q1 2025 | $7.6B | +91% |
| Q4 2024 | -$2.5B | -1630% |
MCK generated $7.1B in free cash flow over the past year, up 12% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
MCK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -2.5M shares |
| 1 year | -6.2% | -7.7M shares |
| 3 years | -13% | -18.1M shares |
| 5 years | -25% | -39.1M shares |
| Available history | -35% | -63.3M shares |
MCK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $894M |
| Q2 2026 | $2.5B |
| Q1 2026 | $2.7B |
| Q4 2025 | $680M |
| Q3 2025 | $818M |
| Q2 2025 | $581M |
| Q1 2025 | $300M |
| Q4 2024 | $827M |
MCK spent $6.8B buying back its own shares over the past year, up 168% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MCK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | 1.5x | Healthy |
MCK's net debt is less than a year of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MCK on leverage, with a lower net debt burden relative to earnings.
MCK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.3 | Overbought |
| Stochastic | 82.8 | Overbought |
MCK's weekly RSI is 76 (overbought) and its Stochastic is 83 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MCK PE vs Healthcare Sector
| Metric | MCK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 7.4% above |
| PE % | 67 | 29 | 38 pts above |
MCK is trading at 28x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MCK on valuation relative to its sector.
MCK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $980.7 | 9.8% above |
| 20 week MA | $906.6 | 19% above |
| 50 week MA | $865.9 | 24% above |
| 100 week MA | $781.2 | 38% above |
| 200 week MA | $628.8 | 71% above |
MCK is in an uptrend: it's above all five of its weekly moving averages, and 71% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MCK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.4 | $170.8 | +22% |
| 2021 | $170.8 | $240.8 | +41% |
| 2022 | $240.8 | $383.7 | +59% |
| 2023 | $383.7 | $463.0 | +21% |
| 2024 | $463.0 | $576.6 | +25% |
| 2025 | $576.6 | $828.3 | +44% |
| 2026 YTD | $828.3 | $1,077.1 | +30% |
MCK has finished every year since 2020 higher, and it's up 30% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MCK on returns for 2026, with the stronger performance.